Name: UMIN ID:
Unique ID issued by UMIN | UMIN000006095 |
---|---|
Receipt number | R000007213 |
Scientific Title | A phase I study of irinotecan for previously treated lung cancer patients with UGT1A1*28 or *6 polymorphism |
Date of disclosure of the study information | 2011/08/01 |
Last modified on | 2021/02/17 20:24:05 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2011/08/01 22:51:36 | ||
2 | Update | 2011/08/23 07:27:18 | UMIN ID1 |
|
3 | Update | 2012/08/08 09:13:40 | Organization1 Address1 Tel1 Email1 |
|
4 | Update | 2014/09/09 10:10:26 | TEL TEL Organization |
|
5 | Update | 2014/09/09 10:10:53 | Recruitment status |
|
6 | Update | 2021/02/17 20:00:48 | Key exclusion criteria |
|
7 | Update | 2021/02/17 20:06:18 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Name of primary person or sponsor Organization Organization Organization Address Address Tel |
|
8 | Update | 2021/02/17 20:13:05 | Recruitment status Date of IRB Last follow-up date |
|
9 | Update | 2021/02/17 20:23:21 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
10 | Update | 2021/02/17 20:24:05 | Results Outcome measures |